nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Epirubicin—bone cancer	0.902	1	CbGbCtD
Fluocinolone Acetonide—PLA2G4A—Raltitrexed—Methotrexate—bone cancer	0.00696	1	CbGdCrCtD
Fluocinolone Acetonide—Fluocinonide—SMO—bone cancer	0.00378	0.426	CrCbGaD
Fluocinolone Acetonide—Telangiectasia—Methotrexate—bone cancer	0.00214	0.0312	CcSEcCtD
Fluocinolone Acetonide—Secondary infection—Epirubicin—bone cancer	0.0016	0.0234	CcSEcCtD
Fluocinolone Acetonide—Taste metallic—Methotrexate—bone cancer	0.00158	0.0232	CcSEcCtD
Fluocinolone Acetonide—Secondary infection—Doxorubicin—bone cancer	0.00148	0.0217	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00132	0.0965	CbGpPWpGaD
Fluocinolone Acetonide—Rash papular—Epirubicin—bone cancer	0.00126	0.0185	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Methotrexate—bone cancer	0.00118	0.0173	CcSEcCtD
Fluocinolone Acetonide—Rash papular—Doxorubicin—bone cancer	0.00117	0.0171	CcSEcCtD
Fluocinolone Acetonide—Impaired healing—Methotrexate—bone cancer	0.00116	0.017	CcSEcCtD
Fluocinolone Acetonide—Abscess—Cisplatin—bone cancer	0.00116	0.017	CcSEcCtD
Fluocinolone Acetonide—Rhinorrhoea—Cisplatin—bone cancer	0.00113	0.0166	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Epirubicin—bone cancer	0.00113	0.0165	CcSEcCtD
Fluocinolone Acetonide—Infection—Carboplatin—bone cancer	0.00111	0.0162	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Epirubicin—bone cancer	0.00111	0.0162	CcSEcCtD
Fluocinolone Acetonide—Fungal skin infection—Doxorubicin—bone cancer	0.00104	0.0153	CcSEcCtD
Fluocinolone Acetonide—Leukoderma—Doxorubicin—bone cancer	0.00102	0.015	CcSEcCtD
Fluocinolone Acetonide—Pain—Carboplatin—bone cancer	0.000954	0.014	CcSEcCtD
Fluocinolone Acetonide—Wheezing—Cisplatin—bone cancer	0.000891	0.013	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Carboplatin—bone cancer	0.000882	0.0129	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Methotrexate—bone cancer	0.000846	0.0124	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Epirubicin—bone cancer	0.000801	0.0117	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Methotrexate—bone cancer	0.000801	0.0117	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Epirubicin—bone cancer	0.000792	0.0116	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNA11—bone cancer	0.000753	0.0549	CbGpPWpGaD
Fluocinolone Acetonide—Folliculitis—Epirubicin—bone cancer	0.000749	0.011	CcSEcCtD
Fluocinolone Acetonide—Lacrimation—Doxorubicin—bone cancer	0.000741	0.0108	CcSEcCtD
Fluocinolone Acetonide—Skin hyperpigmentation—Doxorubicin—bone cancer	0.000733	0.0107	CcSEcCtD
Fluocinolone Acetonide—Folliculitis—Doxorubicin—bone cancer	0.000693	0.0101	CcSEcCtD
Fluocinolone Acetonide—Abscess—Methotrexate—bone cancer	0.000636	0.0093	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signal amplification—GNA11—bone cancer	0.000634	0.0462	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000627	0.0457	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.000617	0.045	CbGpPWpGaD
Fluocinolone Acetonide—Otitis media—Epirubicin—bone cancer	0.000605	0.00885	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Cisplatin—bone cancer	0.000595	0.00871	CcSEcCtD
Fluocinolone Acetonide—Abscess—Epirubicin—bone cancer	0.000595	0.00871	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000592	0.0431	CbGpPWpGaD
Fluocinolone Acetonide—Rash pustular—Epirubicin—bone cancer	0.00059	0.00864	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000565	0.0412	CbGpPWpGaD
Fluocinolone Acetonide—Otitis media—Doxorubicin—bone cancer	0.00056	0.00819	CcSEcCtD
Fluocinolone Acetonide—Abscess—Doxorubicin—bone cancer	0.000551	0.00806	CcSEcCtD
Fluocinolone Acetonide—Rash pustular—Doxorubicin—bone cancer	0.000546	0.00799	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Methotrexate—bone cancer	0.000546	0.00799	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000535	0.039	CbGpPWpGaD
Fluocinolone Acetonide—Viral infection—Epirubicin—bone cancer	0.000521	0.00763	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Epirubicin—bone cancer	0.000511	0.00748	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Epirubicin—bone cancer	0.000511	0.00748	CcSEcCtD
Fluocinolone Acetonide—Budesonide—CYP3A4—bone cancer	0.000497	0.0561	CrCbGaD
Fluocinolone Acetonide—Fluticasone furoate—CYP3A4—bone cancer	0.000488	0.055	CrCbGaD
Fluocinolone Acetonide—Viral infection—Doxorubicin—bone cancer	0.000482	0.00706	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Epirubicin—bone cancer	0.000477	0.00697	CcSEcCtD
Fluocinolone Acetonide—Lacrimation increased—Doxorubicin—bone cancer	0.000473	0.00692	CcSEcCtD
Fluocinolone Acetonide—Herpes simplex—Doxorubicin—bone cancer	0.000473	0.00692	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000468	0.0341	CbGpPWpGaD
Fluocinolone Acetonide—Dermatitis contact—Epirubicin—bone cancer	0.000465	0.00681	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Cisplatin—bone cancer	0.000453	0.00662	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Cisplatin—bone cancer	0.000444	0.00649	CcSEcCtD
Fluocinolone Acetonide—Neck pain—Doxorubicin—bone cancer	0.000441	0.00645	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Epirubicin—bone cancer	0.000435	0.00636	CcSEcCtD
Fluocinolone Acetonide—Dermatitis contact—Doxorubicin—bone cancer	0.000431	0.0063	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Cisplatin—bone cancer	0.00043	0.0063	CcSEcCtD
Fluocinolone Acetonide—Alclometasone—CYP3A4—bone cancer	0.000429	0.0483	CrCbGaD
Fluocinolone Acetonide—Flunisolide—CYP3A4—bone cancer	0.000417	0.047	CrCbGaD
Fluocinolone Acetonide—Mediastinal disorder—Cisplatin—bone cancer	0.000415	0.00607	CcSEcCtD
Fluocinolone Acetonide—Paramethasone—CYP3A4—bone cancer	0.000412	0.0465	CrCbGaD
Fluocinolone Acetonide—Alopecia—Cisplatin—bone cancer	0.000407	0.00595	CcSEcCtD
Fluocinolone Acetonide—Dry eye—Doxorubicin—bone cancer	0.000402	0.00589	CcSEcCtD
Fluocinolone Acetonide—Fluorometholone—CYP3A4—bone cancer	0.000402	0.0453	CrCbGaD
Fluocinolone Acetonide—Malnutrition—Cisplatin—bone cancer	0.000401	0.00586	CcSEcCtD
Fluocinolone Acetonide—Erythema—Cisplatin—bone cancer	0.000401	0.00586	CcSEcCtD
Fluocinolone Acetonide—Methylprednisolone—CYP3A4—bone cancer	0.000389	0.0438	CrCbGaD
Fluocinolone Acetonide—Visual disturbance—Methotrexate—bone cancer	0.000385	0.00564	CcSEcCtD
Fluocinolone Acetonide—Eczema—Epirubicin—bone cancer	0.00038	0.00557	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Epirubicin—bone cancer	0.000379	0.00554	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Cisplatin—bone cancer	0.000378	0.00553	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Endothelins—GNA11—bone cancer	0.00036	0.0262	CbGpPWpGaD
Fluocinolone Acetonide—Eczema—Doxorubicin—bone cancer	0.000352	0.00515	CcSEcCtD
Fluocinolone Acetonide—Eye pain—Doxorubicin—bone cancer	0.00035	0.00513	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Epirubicin—bone cancer	0.00035	0.00512	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Epirubicin—bone cancer	0.000342	0.005	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Epirubicin—bone cancer	0.000342	0.005	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.00033	0.0241	CbGpPWpGaD
Fluocinolone Acetonide—Triamcinolone—CYP3A4—bone cancer	0.000328	0.037	CrCbGaD
Fluocinolone Acetonide—Oedema—Cisplatin—bone cancer	0.000327	0.00479	CcSEcCtD
Fluocinolone Acetonide—Infection—Cisplatin—bone cancer	0.000325	0.00476	CcSEcCtD
Fluocinolone Acetonide—Hypoglycaemia—Doxorubicin—bone cancer	0.000324	0.00474	CcSEcCtD
Fluocinolone Acetonide—Triamcinolone—PTGS2—bone cancer	0.000321	0.0362	CrCbGaD
Fluocinolone Acetonide—Nervous system disorder—Cisplatin—bone cancer	0.000321	0.00469	CcSEcCtD
Fluocinolone Acetonide—Pain in extremity—Doxorubicin—bone cancer	0.000316	0.00463	CcSEcCtD
Fluocinolone Acetonide—Diplopia—Doxorubicin—bone cancer	0.000316	0.00463	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Epirubicin—bone cancer	0.000306	0.00447	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000298	0.00436	CcSEcCtD
Fluocinolone Acetonide—Influenza—Epirubicin—bone cancer	0.000295	0.00432	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Methotrexate—bone cancer	0.000293	0.00429	CcSEcCtD
Fluocinolone Acetonide—Fluticasone Propionate—CYP3A4—bone cancer	0.000293	0.033	CrCbGaD
Fluocinolone Acetonide—Nasopharyngitis—Doxorubicin—bone cancer	0.000283	0.00414	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000282	0.00413	CcSEcCtD
Fluocinolone Acetonide—Infestation—Methotrexate—bone cancer	0.000281	0.00412	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Methotrexate—bone cancer	0.000281	0.00412	CcSEcCtD
Fluocinolone Acetonide—Pain—Cisplatin—bone cancer	0.00028	0.00409	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Epirubicin—bone cancer	0.000275	0.00402	CcSEcCtD
Fluocinolone Acetonide—Prednisolone—CYP3A4—bone cancer	0.000274	0.0309	CrCbGaD
Fluocinolone Acetonide—Influenza—Doxorubicin—bone cancer	0.000273	0.004	CcSEcCtD
Fluocinolone Acetonide—Betamethasone—CYP3A4—bone cancer	0.000269	0.0303	CrCbGaD
Fluocinolone Acetonide—Infestation—Epirubicin—bone cancer	0.000263	0.00385	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Epirubicin—bone cancer	0.000263	0.00385	CcSEcCtD
Fluocinolone Acetonide—Betamethasone—PTGS2—bone cancer	0.000263	0.0296	CrCbGaD
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000262	0.0191	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Cisplatin—bone cancer	0.000259	0.00378	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000254	0.00372	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Epirubicin—bone cancer	0.000247	0.00362	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Doxorubicin—bone cancer	0.000244	0.00357	CcSEcCtD
Fluocinolone Acetonide—Infestation—Doxorubicin—bone cancer	0.000244	0.00357	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Methotrexate—bone cancer	0.000244	0.00356	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Cisplatin—bone cancer	0.000241	0.00353	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.000239	0.0174	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.000238	0.0174	CbGpPWpGaD
Fluocinolone Acetonide—Rhinitis—Epirubicin—bone cancer	0.000237	0.00347	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Methotrexate—bone cancer	0.000236	0.00346	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Epirubicin—bone cancer	0.000232	0.0034	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000231	0.0168	CbGpPWpGaD
Fluocinolone Acetonide—Sinusitis—Doxorubicin—bone cancer	0.000229	0.00335	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Epirubicin—bone cancer	0.000228	0.00333	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Methotrexate—bone cancer	0.000228	0.00333	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Cisplatin—bone cancer	0.000224	0.00327	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Methotrexate—bone cancer	0.000223	0.00327	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Methotrexate—bone cancer	0.000221	0.00324	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Epirubicin—bone cancer	0.000221	0.00323	CcSEcCtD
Fluocinolone Acetonide—Erythema—Methotrexate—bone cancer	0.00022	0.00322	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Methotrexate—bone cancer	0.00022	0.00322	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Doxorubicin—bone cancer	0.000219	0.00321	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Methotrexate—bone cancer	0.000215	0.00315	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Doxorubicin—bone cancer	0.000215	0.00315	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Epirubicin—bone cancer	0.000213	0.00312	CcSEcCtD
Fluocinolone Acetonide—Back pain—Methotrexate—bone cancer	0.000213	0.00311	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Doxorubicin—bone cancer	0.000211	0.00309	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Epirubicin—bone cancer	0.000209	0.00306	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000208	0.0152	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Cisplatin—bone cancer	0.000208	0.00304	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Methotrexate—bone cancer	0.000207	0.00303	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Epirubicin—bone cancer	0.000207	0.00303	CcSEcCtD
Fluocinolone Acetonide—Rash—Cisplatin—bone cancer	0.000206	0.00302	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Cisplatin—bone cancer	0.000206	0.00302	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Epirubicin—bone cancer	0.000206	0.00301	CcSEcCtD
Fluocinolone Acetonide—Erythema—Epirubicin—bone cancer	0.000206	0.00301	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Doxorubicin—bone cancer	0.000204	0.00299	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Epirubicin—bone cancer	0.000202	0.00295	CcSEcCtD
Fluocinolone Acetonide—Back pain—Epirubicin—bone cancer	0.000199	0.00291	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Methotrexate—bone cancer	0.000198	0.00289	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Doxorubicin—bone cancer	0.000197	0.00289	CcSEcCtD
Fluocinolone Acetonide—Nausea—Cisplatin—bone cancer	0.000194	0.00284	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Epirubicin—bone cancer	0.000194	0.00284	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Doxorubicin—bone cancer	0.000193	0.00283	CcSEcCtD
Fluocinolone Acetonide—Cough—Methotrexate—bone cancer	0.000192	0.00281	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Doxorubicin—bone cancer	0.000192	0.0028	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGF Pathway—JUN—bone cancer	0.000191	0.0139	CbGpPWpGaD
Fluocinolone Acetonide—Erythema—Doxorubicin—bone cancer	0.00019	0.00279	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Doxorubicin—bone cancer	0.00019	0.00279	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00019	0.0139	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Methotrexate—bone cancer	0.000187	0.00274	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Doxorubicin—bone cancer	0.000187	0.00273	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Epirubicin—bone cancer	0.000185	0.00271	CcSEcCtD
Fluocinolone Acetonide—Back pain—Doxorubicin—bone cancer	0.000184	0.0027	CcSEcCtD
Fluocinolone Acetonide—Cough—Epirubicin—bone cancer	0.00018	0.00263	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Doxorubicin—bone cancer	0.00018	0.00263	CcSEcCtD
Fluocinolone Acetonide—Infection—Methotrexate—bone cancer	0.000178	0.00261	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Methotrexate—bone cancer	0.000176	0.00258	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Epirubicin—bone cancer	0.000175	0.00256	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—PTGS2—bone cancer	0.000174	0.0127	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Doxorubicin—bone cancer	0.000171	0.0025	CcSEcCtD
Fluocinolone Acetonide—Oedema—Epirubicin—bone cancer	0.000168	0.00246	CcSEcCtD
Fluocinolone Acetonide—Infection—Epirubicin—bone cancer	0.000167	0.00244	CcSEcCtD
Fluocinolone Acetonide—Cough—Doxorubicin—bone cancer	0.000166	0.00243	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Epirubicin—bone cancer	0.000165	0.00241	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000164	0.00239	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP2—bone cancer	0.000162	0.0118	CbGpPWpGaD
Fluocinolone Acetonide—Arthralgia—Doxorubicin—bone cancer	0.000162	0.00237	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000162	0.0118	CbGpPWpGaD
Fluocinolone Acetonide—Dexamethasone—CYP3A4—bone cancer	0.000156	0.0176	CrCbGaD
Fluocinolone Acetonide—Oedema—Doxorubicin—bone cancer	0.000155	0.00227	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000155	0.00227	CcSEcCtD
Fluocinolone Acetonide—Infection—Doxorubicin—bone cancer	0.000154	0.00226	CcSEcCtD
Fluocinolone Acetonide—Pain—Methotrexate—bone cancer	0.000154	0.00225	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000153	0.00224	CcSEcCtD
Fluocinolone Acetonide—Dexamethasone—PTGS2—bone cancer	0.000153	0.0172	CrCbGaD
Fluocinolone Acetonide—Nervous system disorder—Doxorubicin—bone cancer	0.000152	0.00223	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000147	0.0107	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000145	0.00212	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000144	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Epirubicin—bone cancer	0.000144	0.0021	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Methotrexate—bone cancer	0.000142	0.00208	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000142	0.00207	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	0.000139	0.0101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000138	0.01	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000134	0.00978	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000134	0.00196	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	0.000134	0.00974	CbGpPWpGaD
Fluocinolone Acetonide—Pain—Doxorubicin—bone cancer	0.000133	0.00194	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Epirubicin—bone cancer	0.000133	0.00194	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000132	0.00965	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Methotrexate—bone cancer	0.000132	0.00194	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000132	0.0096	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—JUN—bone cancer	0.00013	0.00949	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Methotrexate—bone cancer	0.000127	0.00186	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—JUN—bone cancer	0.000125	0.00914	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Epirubicin—bone cancer	0.000124	0.00181	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Doxorubicin—bone cancer	0.000123	0.0018	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Methotrexate—bone cancer	0.000123	0.0018	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—MMP9—bone cancer	0.000122	0.0089	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000122	0.00887	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000119	0.0087	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Epirubicin—bone cancer	0.000119	0.00174	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Methotrexate—bone cancer	0.000119	0.00174	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000117	0.00852	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Epirubicin—bone cancer	0.000115	0.00168	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Gene Expression—ZNF77—bone cancer	0.000115	0.00837	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Doxorubicin—bone cancer	0.000115	0.00168	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Methotrexate—bone cancer	0.000114	0.00167	CcSEcCtD
Fluocinolone Acetonide—Rash—Methotrexate—bone cancer	0.000113	0.00166	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Methotrexate—bone cancer	0.000113	0.00165	CcSEcCtD
Fluocinolone Acetonide—Headache—Methotrexate—bone cancer	0.000112	0.00165	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000112	0.00818	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Epirubicin—bone cancer	0.000111	0.00163	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Doxorubicin—bone cancer	0.00011	0.00161	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Epirubicin—bone cancer	0.000107	0.00156	CcSEcCtD
Fluocinolone Acetonide—Nausea—Methotrexate—bone cancer	0.000107	0.00156	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Doxorubicin—bone cancer	0.000106	0.00156	CcSEcCtD
Fluocinolone Acetonide—Rash—Epirubicin—bone cancer	0.000106	0.00155	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Epirubicin—bone cancer	0.000106	0.00155	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	0.000106	0.00771	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Epirubicin—bone cancer	0.000105	0.00154	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—BRAF—bone cancer	0.000103	0.00753	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Doxorubicin—bone cancer	0.000103	0.0015	CcSEcCtD
Fluocinolone Acetonide—Nausea—Epirubicin—bone cancer	9.98e-05	0.00146	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Doxorubicin—bone cancer	9.88e-05	0.00145	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—EGFR—bone cancer	9.87e-05	0.00719	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Doxorubicin—bone cancer	9.8e-05	0.00143	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Doxorubicin—bone cancer	9.79e-05	0.00143	CcSEcCtD
Fluocinolone Acetonide—Headache—Doxorubicin—bone cancer	9.74e-05	0.00142	CcSEcCtD
Fluocinolone Acetonide—Nausea—Doxorubicin—bone cancer	9.23e-05	0.00135	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NDUFA12—bone cancer	8.75e-05	0.00638	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	8.59e-05	0.00626	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—JUN—bone cancer	8.47e-05	0.00617	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.32e-05	0.00606	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	8.24e-05	0.00601	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	8.08e-05	0.00589	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	7.54e-05	0.00549	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—JUN—bone cancer	7.53e-05	0.00549	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	7.46e-05	0.00544	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—SPARC—bone cancer	7.43e-05	0.00541	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—NT5C3A—bone cancer	7.25e-05	0.00528	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GRM4—bone cancer	6.98e-05	0.00508	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—RGS1—bone cancer	6.98e-05	0.00508	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—RB1—bone cancer	6.97e-05	0.00508	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—GNA11—bone cancer	6.79e-05	0.00495	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.17e-05	0.0045	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IL3—bone cancer	6.16e-05	0.00449	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GRM1—bone cancer	6.05e-05	0.00441	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	5.95e-05	0.00433	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—FUS—bone cancer	5.61e-05	0.00409	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TP53—bone cancer	5.59e-05	0.00407	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.36e-05	0.00391	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	4.93e-05	0.00359	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	4.46e-05	0.00325	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—SMO—bone cancer	4.26e-05	0.00311	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.22e-05	0.00307	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RGS1—bone cancer	4.12e-05	0.003	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GRM4—bone cancer	4.12e-05	0.003	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PLAU—bone cancer	4.04e-05	0.00294	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—GNA11—bone cancer	3.9e-05	0.00284	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—NR1I2—bone cancer	3.89e-05	0.00283	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GRM1—bone cancer	3.57e-05	0.0026	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.54e-05	0.00258	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL3—bone cancer	3.53e-05	0.00258	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ENO2—bone cancer	3.18e-05	0.00231	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—DHFR—bone cancer	2.95e-05	0.00215	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—EIF2S1—bone cancer	2.87e-05	0.00209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GNA11—bone cancer	2.75e-05	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SMO—bone cancer	2.52e-05	0.00183	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP3A4—bone cancer	2.5e-05	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—EZH2—bone cancer	2.49e-05	0.00182	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.48e-05	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—GNA11—bone cancer	2.3e-05	0.00168	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ATF1—bone cancer	2.14e-05	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GSTP1—bone cancer	2.14e-05	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL3—bone cancer	2.09e-05	0.00152	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFBR2—bone cancer	1.79e-05	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IGF1R—bone cancer	1.68e-05	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TP53—bone cancer	1.62e-05	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KIT—bone cancer	1.22e-05	0.000888	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—BRAF—bone cancer	1.15e-05	0.000834	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—EGFR—bone cancer	1.11e-05	0.000809	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PTGS2—bone cancer	1.11e-05	0.000806	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MDM2—bone cancer	9.59e-06	0.000699	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—JUN—bone cancer	8.34e-06	0.000608	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MMP9—bone cancer	8.11e-06	0.000591	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—EGFR—bone cancer	6.56e-06	0.000478	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TP53—bone cancer	5.51e-06	0.000401	CbGpPWpGaD
